S&P 500's biggest R&D spenders; Roka Bioscience grabs $20M round;

@FierceBiotech: Baxter sets up $200M venture arm for early-stage investments. Item | Follow @FierceBiotech

@JohnCFierce: Merck is killing telcagepant, its migraine drug, after Ph3 data analysis. News | Follow @JohnCFierce

@RyanMFierce: More Biogen coverage to come after trip to Boston, but first catching up on pipeline priorities. Story | Follow @RyanMFierce

@MaureenFierce: New drugs trump mammograms for fewer cancer deaths. Article | Follow @MaureenFierce

> Drug giants and tech titans top the list of the S&P 500's largest R&D spenders. Post

> Roka Bioscience has reeled in $20 million in a Series C round of financing as the Gen-Probe spinoff pursues commercialization of its molecular assays. Release

> The North Carolina Biotechnology Center is shipping $1.4 million in grants to 6 universities in the state. Report

> RaQualia Pharma reports that it has licensed its 5-HT4 partial agonist, dubbed RQ-00000010, to CJ CheilJedang for development and commercialization in China, India, Korea and Southeast Asia. Announcement

> San Diego-based Sorrento Therapeutics has garnered a two-year, $600,000 Phase I Small Business Technology Transfer Research grant from the NIH to study antibody treatments and vaccines against C. difficile infections. Item

Pharma News

@FiercePharma: Yervoy hits the market with $95M bang. Story | Follow @FiercePharma

> Pfizer readies bidding info for nutritionals auction. Article

> Charred shrink wrap detected in Merck vax vials. More

> Incivek storms hep C market with $75M launch. News

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.